ProfileGDS5678 / 1440830_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 95% 93% 93% 93% 94% 86% 90% 89% 88% 95% 97% 95% 96% 96% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.3664295
GSM967853U87-EV human glioblastoma xenograft - Control 27.8264393
GSM967854U87-EV human glioblastoma xenograft - Control 37.9682893
GSM967855U87-EV human glioblastoma xenograft - Control 48.1672693
GSM967856U87-EV human glioblastoma xenograft - Control 58.1595894
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.3206386
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.009690
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.0751989
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.7882288
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.5966795
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 29.1686497
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.6020395
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.9483296
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 58.7905296